Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Caen cedex, France Clinical Trials

A listing of Caen cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (268) clinical trials

Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease

Crohn's disease is a chronic, inflammatory disorder affecting any part of the gastrointestinal tract but the terminal ileum is the most frequent location involved alone or in combination with other locations. While about one half of patients have involvement of the ileum and large bowel, another third have disease limited …

Phase N/A

0.0 miles

Learn More »

Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET

NUMBER OF PATIENTS: 200 patients INCLUSION PERIOD: 33 months STUDY DURATION: 57 months MAIN EVALUATION Primary endpoints Week 10-54: proportion of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at week 54 Data base lock, data analysis and display (publication) will happen when all included …

Phase

0.0 miles

Learn More »

Phase II Study of Regorafenib as Maintenance Therapy

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors: Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype Response to doxorubicin-based chemotherapy: partial response versus stable disease Centers The treatment will be administrated as long as it …

Phase

0.0 miles

Learn More »

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed Stage III Subjects With Locally Advanced Unresectable Non-small Cell Lung Cancer

This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab given sequentially after cCRT versus cCRT alone, in newly diagnosed stage III subjects with locally …

Phase

0.0 miles

Learn More »

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Patients diagnosed with …

Phase

0.0 miles

Learn More »

Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

This study will compare the clinical activity of novel immune-oncology agents (in combination or as single agents) to standard of care in participants with relapsed/refractory advanced NSCLC. The study will initially evaluate two treatment regimens/arms. Additional regimens/arms may be added via future protocol amendment(s). Participants will be stratified by histology …

Phase

0.0 miles

Learn More »

Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Phase

0.0 miles

Learn More »

Rendering of a Local 1g Environment for Enhanced Motor Learning in Altered Gravity

Human motor adaptation is crucial to adapt to new environments, such as altered gravity. Dexterous manipulation and fine movements in space require learning new coordinated motor actions. Traditionally, adaptation mechanisms have been tested in laboratories with robotic devices that perturb specific task parameters unbeknownst to the participant. Over repetition, participants …

Phase N/A

0.0 miles

Learn More »

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+ HER2- Advanced Breast Cancer

QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing …

Phase

0.0 miles

Learn More »

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Phase

0.0 miles

Learn More »